1/6
07:07 am
blte
Belite Bio (NASDAQ:BLTE) was given a new $191.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
Low
Report
Belite Bio (NASDAQ:BLTE) was given a new $191.00 price target on by analysts at Morgan Stanley. They now have an "overweight" rating on the stock.
1/4
01:06 am
blte
12/27
01:05 am
blte
Medium
Report
12/4
12:31 am
blte
Has Belite Bio's 134% 2025 Surge Fully Reflected Its DCF and Book Value Picture [Yahoo! Finance]
Low
Report
Has Belite Bio's 134% 2025 Surge Fully Reflected Its DCF and Book Value Picture [Yahoo! Finance]
12/3
01:15 pm
blte
Belite Bio (NASDAQ:BLTE) was given a new $187.00 price target on by analysts at BTIG Research.
Low
Report
Belite Bio (NASDAQ:BLTE) was given a new $187.00 price target on by analysts at BTIG Research.
12/3
12:05 pm
blte
Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Low
Report
Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at Benchmark Co..
12/3
07:57 am
blte
Belite Bio (NASDAQ:BLTE) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
Low
Report
Belite Bio (NASDAQ:BLTE) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.
12/2
05:10 pm
blte
Belite Bio (NASDAQ:BLTE) was given a new $200.00 price target on by analysts at Maxim Group.
Low
Report
Belite Bio (NASDAQ:BLTE) was given a new $200.00 price target on by analysts at Maxim Group.
12/2
07:08 am
blte
Belite Bio (NASDAQ:BLTE) was given a new $194.00 price target on by analysts at Mizuho.
Medium
Report
Belite Bio (NASDAQ:BLTE) was given a new $194.00 price target on by analysts at Mizuho.
12/1
10:37 pm
blte
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
Low
Report
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
12/1
04:26 pm
blte
Belite Bio announces proposed underwritten public offering of ADSs [Seeking Alpha]
Medium
Report
Belite Bio announces proposed underwritten public offering of ADSs [Seeking Alpha]
12/1
04:20 pm
blte
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
Medium
Report
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
12/1
02:25 pm
blte
Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript [Seeking Alpha]
Low
Report
Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript [Seeking Alpha]
12/1
12:10 pm
blte
Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/1
06:00 am
blte
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
High
Report
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
11/24
09:23 am
blte
Belite Bio (NASDAQ:BLTE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $154.00 price target on the stock.
Medium
Report
Belite Bio (NASDAQ:BLTE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $154.00 price target on the stock.
11/20
08:43 am
blte
Belite Bio (NASDAQ:BLTE) is now covered by analysts at Mizuho. They set a "neutral" rating and a $105.00 price target on the stock.
Medium
Report
Belite Bio (NASDAQ:BLTE) is now covered by analysts at Mizuho. They set a "neutral" rating and a $105.00 price target on the stock.
11/17
01:42 pm
blte
Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight [Yahoo! Finance]
Low
Report
Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight [Yahoo! Finance]
11/15
06:41 am
blte
Belite Bio (BLTE): Exploring Valuation Following Recent Share Price Surge [Yahoo! Finance]
Low
Report
Belite Bio (BLTE): Exploring Valuation Following Recent Share Price Surge [Yahoo! Finance]
11/15
01:42 am
blte
11/11
12:30 am
blte
Belite Bio Inc (BLTE) Q3 2025 Earnings Call Highlights: Clinical Trials Progress and Financial ... [Yahoo! Finance]
Medium
Report
Belite Bio Inc (BLTE) Q3 2025 Earnings Call Highlights: Clinical Trials Progress and Financial ... [Yahoo! Finance]
11/10
06:14 pm
blte
Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/10
03:35 pm
blte
Belite Bio GAAP EPS of -$0.28 beats by $0.20 [Seeking Alpha]
Low
Report
Belite Bio GAAP EPS of -$0.28 beats by $0.20 [Seeking Alpha]
11/10
08:46 am
blte
Belite Bio GAAP EPS of -$0.28 [Seeking Alpha]
Medium
Report
Belite Bio GAAP EPS of -$0.28 [Seeking Alpha]
11/10
08:00 am
blte
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Medium
Report
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update